Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
NCT ID: NCT00097812
Last Updated: 2012-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2004-05-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
NCT00100555
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
NCT00718861
Intra-venous Zoledronic Acid Once Yearly
NCT00984893
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
NCT00132808
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zoledronic acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be osteopenic/osteoporotic
* Treatment with oral bisphosphonate for at least 1 year
Exclusion Criteria
* Treatment with other bone active agents
45 Years
79 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Permanente Medical Group
Santa Rosa, California, United States
Colorado Center for Bone Research
Lakewood, Colorado, United States
Florida Medical Research Institute
Gainsville, Florida, United States
Radiant Research
Stuart, Florida, United States
University of Kansas School of Medicine/ Division of Endocrinology
Kansas City, Kansas, United States
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States
Arthritis Center of Nebraska
Lincoln, Nebraska, United States
Creighton University Osteoporosis Research Center
Omaha, Nebraska, United States
Oregon Osteoporosis Center
Portland, Oregon, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Radiant Research
Wyomissing, Pennsylvania, United States
Puget Sound Osteoporosis Center
Seattle, Washington, United States
Novartis
Nuremberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CZOL446H2313
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.